Lilly ditches tabalumab after another Phase III trial fails
This article was originally published in Scrip
Executive Summary
Lilly has thrown in the towel on development of its anti-BAFF product tabalumab after it disappointed in Phase III in a second indication, systemic lupus erythematosus (SLE). Its development in rheumatoid arthritis had previously been dropped at the Phase III stage (scripintelligence.com, 8 February 2013).